The Journal club returns for a Halloween special and this time around, Dr. Oliver Medvedik is taking an in depth look at a recent paper which showed a combination of three drugs had a synergistic effect and increased lifespan greatly in fruit flies. The drugs all target parts of the nutrient sensing system which controls…

Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it’s named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved…

Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA. Targeting the mTOR pathway of…

Today, we are pleased to announce that the results are in from a human trial that targets the aging immune system and that an immune system-boosting drug appears to be effective. Targeting TORC1 to boost the immune system As we age, the immune system becomes increasingly poor and unable to detect and fight infections. This…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD